[IV iron or oral iron in anaemic patient with CKD]

Area of Science:

• Nephrology
• Hematology
• Internal Medicine

Context:

• Iron deficiency and anemia are prevalent in all stages of chronic kidney disease (CKD).
• Oral iron supplement bioavailability is variable and often insufficient for CKD patients.
• Current treatment guidelines recommend specific hemoglobin and transferrin saturation targets.

Purpose:

• To evaluate the efficacy and safety of iron supplementation in chronic kidney disease patients.
• To compare oral versus intravenous iron administration for anemia management in CKD.
• To determine the optimal iron therapy to achieve target hematological parameters.

Summary:

• Population-based studies confirm high rates of iron deficiency and anemia in CKD.
• Intravenous (i.v.) iron demonstrates superior efficacy over oral iron in CKD patients.
• The safety profile of i.v. iron sucrose is well-established.
• Achieving recommended targets (Hb > 11 g/dl, transferrin saturation > 20%) often requires i.v. iron therapy.

Impact:

• Highlights the limitations of oral iron in CKD anemia management.
• Supports the use of intravenous iron for achieving therapeutic goals in CKD.
• Informs clinical practice guidelines for optimizing anemia treatment in kidney disease patients.